BRD4/CK2-IN-1

• CAT Number: I045158
• CAS Number: 2756851-99-5
• Molecular Formula: C29H30ClN5O5
• Molecular Weight: 564.03
• Purity: ≥95%
• Synonyms: N-[3-chloro-4-(4-methylpiperazin-1-yl)phenyl]-2-[4-(5,7-dimethoxy-4-oxo-3H-quinazolin-2-yl)phenoxy]acetamide
• InChI: InChI=1S/C29H30ClN5O5/c1-34-10-12-35(13-11-34)24-9-6-19(14-22(24)30)31-26(36)17-40-20-7-4-18(5-8-20)28-32-23-15-21(38-2)16-25(39-3)27(23)29(37)33-28/h4-9,14-16H,10-13,17H2,1-3H3,(H,31,36)(H,32,33,37)
• InChIKey: UZWCUBDJHDWTFV-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=C(C=C(C=C2)NC(=O)COC3=CC=C(C=C3)C4=NC5=C(C(=CC(=C5)OC)OC)C(=O)N4)Cl

BRD4/CK2-IN-1（Cat No.:I045158）is a potent dual inhibitor targeting bromodomain-containing protein 4 (BRD4) and casein kinase 2 (CK2), two key regulators of transcription and cell signaling. By binding to BRD4, it disrupts BET-dependent transcription of oncogenes, while CK2 inhibition interferes with phosphorylation-driven survival pathways. This combined blockade suppresses cancer cell proliferation, induces apoptosis, and modulates inflammatory responses. BRD4/CK2-IN-1 demonstrates therapeutic potential in oncology and immune-related disorders, offering a synergistic strategy to target both epigenetic regulation and kinase-mediated signaling in disease models.